Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet
Pressmeddelande

Redeye: Enzymatica Q1 2023 - A step in the right direction

Enzymatica

Redeye provides an update in relation to Enzymatica’s Q1 2023 report. Even if the report was a bit under our expectations, we are positive that the negative effects of the pandemic seem to disappear gradually. The sales during the quarter were SEK13.0m (SEK4.2m), a bit lower than our sales estimate of SEK16.2m, and EBIT came in at SEK-14.4m (SEK-18.1m) compared to our EBIT estimate of SEK-9.7m. We have only made minor changes in our sales and OPEX estimates for 2023. The changes do not render a difference in our valuation; therefore, we reiterate our base case of SEK6.5.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Enzymatica Q1 2023 - A step in the right direction

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.